First US Trial of Bone-marrow Stem Cells for Heart Attack Patients Proves Safe

Author: Minneapolis Heart Institute Foundation
Published: 2010/09/14 - Updated: 2018/05/29
Topic: Regenerative Medicine - Publications List

Page Content: Synopsis - Introduction - Main

Synopsis: Adult stem cells derived from a patient bone marrow presents a potential new type of therapy to benefit individuals after a heart attack.

Introduction

The first randomized, placebo-controlled U.S. clinical trial to assess the use of bone marrow-derived mononuclear cells (BMC) in patients after a ST-elevation myocardial infarction (STEMI; severe heart attack) demonstrated a strong safety profile for this cell therapy, based on phase 1 results published in the September issue of the American Heart Journal.

Main Item

"The use of adult stem cells, derived from the patient's own bone marrow, presents a potential new type of therapy to benefit individuals after they suffer a heart attack," says the study's principal investigator Jay H. Traverse, MD, cardiologist at the Minneapolis Heart Institute® at Abbott Northwestern Hospital in Minneapolis, Minn. "Also, these types of stem cells do not possess any of the ethical concerns of embryonic stem cell research."

"While the objective of phase 1 clinical trials is to assess safety, researchers also look for hints of efficacy that have been revealed in previous studies," says Traverse. "Based on indications of some improvements in various European studies, we sought to examine whether this therapy could improve ejection fraction at six months, and whether it had an effect on attenuating adverse left ventricular remodeling as measured by cardiac MRI."

In this single-center trial, the researchers enrolled 40 patients with STEMI, randomizing them in a 3:1 ratio to 100 million autologous BMCs versus placebo, administered three to ten days following successful primary angioplasty and stenting of the left anterior descending coronary artery.

Importantly, the researchers elected to deliver cells by an intracoronary infusion as opposed to the stop-flow technique that had been used in all preceding trials and all patients received an identical number of cells.

Administration of BMC was safely performed in all patients with minimal major adverse clinical event rates, and all patients remain alive to date, Traverse and colleagues reported.

While the BMC cell therapy was associated with a significant improvement in left ventricular ejection fraction at six months (49% to 55.2%), the study failed to demonstrate that the cell therapy was superior to placebo because of the similar improvement in the small placebo group (48.6% to 57%). However, the BMC group experienced a significant improvement in left-ventricular volumes at six months compared with the placebo group.

"A review of the available clinical literature reveals a split in the benefit of left ventricular ejection fraction some studies show no benefit and others show a small improvement," Traverse explains. "Any number of factors can influence this outcome: the way the ejection fraction is measured, the timing of BMC administration, how many cells are delivered, the type of STEMI patient population. There are a lot of variables, leading some to question whether ejection fraction is the most appropriate endpoint for cell therapy trials."

"To this point, no study has been properly powered to assess the appropriate timing of BMC administration after a heart attack," says Traverse.

However, Traverse and his colleagues at the Minneapolis Heart Institute® are involved with the TIME trial, sponsored by the National Heart, Lung and Blood Institute's Cardiovascular Cell Therapy Research Network (CCTRN), which is randomizing patients to BMCs at three or seven days post-STEMI to determine the most appropriate timing to administer the stem cells following a heart attack.

This study was supported by the Jon H. Dehaan Foundation. Cell processing was supported by the Production Assistance for Cellular Therapies. The infusion catheters were supplied by Boston Scientific, headquartered in Natick, Mass.

Attribution/Source(s): This quality-reviewed publication was selected for publishing by the editors of Disabled World (DW) due to its relevance to the disability community. Originally authored by Minneapolis Heart Institute Foundation and published on 2010/09/14, this content may have been edited for style, clarity, or brevity. For further details or clarifications, Minneapolis Heart Institute Foundation can be contacted at NOTE: Disabled World does not provide any warranties or endorsements related to this article.

Explore Similar Topics

- A groundbreaking code of practice has been introduced for the use of stem cell-based embryo models in research.

- Human pluripotent stem cells in a lab can initiate a process resembling the gastrulation phase - where cells begin differentiating into new cell types - much earlier than occurs in mother nature.

Citing Information and Page References

Disabled World (DW) is a comprehensive online resource providing information and news related to disabilities, assistive technologies, and accessibility. Founded in 2004 our website covers a wide range of topics, including disability rights, healthcare, education, employment, and independent living, with the goal of supporting the disability community and their families.

Cite This Page (APA): Minneapolis Heart Institute Foundation. (2010, September 14 - Last revised: 2018, May 29). First US Trial of Bone-marrow Stem Cells for Heart Attack Patients Proves Safe. Disabled World (DW). Retrieved February 12, 2025 from www.disabled-world.com/news/research/stemcells/heart-attack-stemcells.php

Permalink: <a href="https://www.disabled-world.com/news/research/stemcells/heart-attack-stemcells.php">First US Trial of Bone-marrow Stem Cells for Heart Attack Patients Proves Safe</a>: Adult stem cells derived from a patient bone marrow presents a potential new type of therapy to benefit individuals after a heart attack.

While we strive to provide accurate and up-to-date information, it's important to note that our content is for general informational purposes only. We always recommend consulting qualified healthcare professionals for personalized medical advice. Any 3rd party offering or advertising does not constitute an endorsement.